An updated pocket card on obesity (anti-obesity) medicines for pharmacy and medical students: who needs treatment, doses of injectable and oral drugs, expected weight loss, when to stop, side effects and safety, including the new oral options approved in 2025 and 2026.
- General rule: BMI 30 or more, or BMI 27 or more with a weight-related problem (diabetes, high BP, sleep apnoea, fatty liver, knee arthritis, heart disease)
- South Asians (Pakistan): risk starts at a lower BMI; NICE lowers BMI cut-offs by 2.5 for South Asian and other at-risk groups (obesity from 27.5); also check waist (over 90 cm men, 80 cm women) or waist-to-height ratio 0.5 or more
- Always with: reduced-calorie diet, more activity, sleep and behaviour support
- Goal: 5 to 10% loss improves BP, sugar and fats; 15% or more can put diabetes into remission and treat sleep apnoea
- Not for: pregnancy, breastfeeding, cosmetic weight loss at normal BMI
- Big Tirzepatide (GIP/GLP-1) weekly: 2.5 mg for 4 weeks, then up by 2.5 mg every 4 weeks to 5, 10 or 15 mg; about 20% loss
- Big Semaglutide 2.4 mg weekly: 0.25, 0.5, 1, 1.7 then 2.4 mg, each step 4 weeks; about 15% loss; reduces heart attack and stroke by 20% (SELECT)
- Small Liraglutide 3 mg daily: 0.6 mg, up by 0.6 mg each week to 3 mg; about 8% loss; generics available
- Missed weekly dose: take within 4 to 5 days; if longer, skip and take the next one on the usual day
- Big Oral semaglutide 25 mg: once daily, on waking with a little water, 30 min before food or other medicine; 1.5 mg, then 4 mg, 9 mg and 25 mg, each step 30 days; about 14 to 17% loss
- Mid Orforglipron: once daily non-peptide GLP-1 pill; no food or water timing; tablets start at 0.8 mg and are increased gradually to a maintenance dose of 5.5, 9 or 17.2 mg (called 6, 12 and 36 mg in the trials); about 11 to 12% loss at the top dose
- Small Orlistat: 120 mg TDS with fatty meals; blocks fat absorption; about 3% loss; take a multivitamin at bedtime
- Small Naltrexone/bupropion: 8/90 mg tablets stepped up to 2 tablets BD; about 5% loss; not with seizures, opioids or uncontrolled BP
- Mid Phentermine/topiramate: stepped dose once daily; about 9% loss; not in pregnancy (birth defects), glaucoma or heart disease
- Review at 3 to 6 months: on the full or maximum tolerated dose: continue if 5% or more weight lost (NICE: consider stopping semaglutide if under 5% at 6 months)
- Poor response: check adherence and diet; switch to a stronger drug or refer
- Long-term: obesity is chronic: most people regain weight within a year of stopping
- Plateau: weight usually stops falling after 12 to 18 months; this is expected
- Surgery: consider bariatric surgery for BMI 35 or more (or 30 or more with type 2 diabetes; lower in South Asians)
- Stomach: nausea, vomiting, diarrhoea, constipation: worst after each dose step; eat small meals, stop when full, avoid fatty food
- Serious: pancreatitis (severe belly pain to back: stop), gallstones, dehydration with kidney injury
- Muscle loss: eat enough protein (1 to 1.2 g/kg/day) and do strength exercise
- Diabetes: reduce sulfonylurea or insulin dose to avoid hypoglycaemia
- Eyes: rapid sugar fall can worsen diabetic retinopathy: eye check
- Mood: report new depression or suicidal thoughts
- Do not use: personal or family history of medullary thyroid cancer or MEN2; previous pancreatitis (caution); pregnancy
- Pregnancy plan: stop semaglutide at least 2 months before trying to conceive
- Contraception: tirzepatide can reduce the pill: use a non-oral method or add condoms for 4 weeks after starting and after each dose increase
- Surgery: tell the anaesthetist: slow stomach emptying raises aspiration risk
- Fake products: buy only from licensed pharmacies; avoid unregulated "compounded" or online pens
Details behind the card
1. What is new in 2025 and 2026?
- Weight-loss pills: oral semaglutide 25 mg was approved in the US in December 2025, and orforglipron, the first non-peptide oral GLP-1 that can be taken with or without food, in April 2026.
- Beyond weight: semaglutide reduces heart attacks and strokes in people with heart disease and obesity; tirzepatide is approved for obstructive sleep apnoea; both help heart failure with preserved ejection fraction (HFpEF) and obesity.
- Diabetes guidelines (ADA 2026) now treat weight loss as a main treatment goal in type 2 diabetes.
- Coming soon: combination drugs such as cagrilintide + semaglutide (CagriSema) and triple agonists are in late trials or under review.
2. Anti-obesity drugs at a glance
| Drug | How it works | Route | Avg. weight loss | Key points |
|---|---|---|---|---|
| Tirzepatide | GIP + GLP-1 receptor agonist | SC weekly | about 20% | Largest loss; also for sleep apnoea and diabetes |
| Semaglutide 2.4 mg | GLP-1 receptor agonist | SC weekly | about 15% | Proven heart benefit |
| Oral semaglutide 25 mg | GLP-1 receptor agonist | Oral daily | about 14 to 17% | Strict empty-stomach rules |
| Orforglipron | Non-peptide GLP-1 agonist | Oral daily | about 11 to 12% | No food rules |
| Liraglutide 3 mg | GLP-1 receptor agonist | SC daily | about 8% | Cheaper generics; approved from age 12 |
| Phentermine/topiramate | Appetite suppressant + anticonvulsant | Oral daily | about 9% | Not in pregnancy or heart disease |
| Naltrexone/bupropion | Opioid antagonist + antidepressant | Oral twice daily | about 5% | Can raise BP; seizure risk |
| Orlistat | Lipase inhibitor (blocks fat absorption) | Oral 3 times daily | about 3% | Oily stools; fat-soluble vitamin loss |
3. How GLP-1 type drugs cause weight loss
They act on the brain to reduce hunger and increase fullness, slow stomach emptying, and help the pancreas release insulin only when sugar is high. Tirzepatide adds GIP action, which gives extra weight loss. Because they work through appetite, people still need a healthy diet with enough protein, fruit and vegetables.
4. Counselling checklist
- Increase the dose slowly; do not jump steps to lose weight faster.
- Eat slowly, stop when full, avoid large fatty or spicy meals, and drink enough water.
- Rotate injection sites (abdomen, thigh, upper arm); store pens as the label says.
- Seek help for severe belly pain, persistent vomiting, yellow eyes or signs of dehydration.
- Keep exercising, especially strength training, to protect muscle.
- Expect weight regain if the medicine is stopped; plan long-term with the doctor.
5. Special groups
- Type 2 diabetes: semaglutide or tirzepatide treat both sugar and weight; lower insulin or sulfonylurea doses when starting.
- Adolescents: semaglutide 2.4 mg and liraglutide 3 mg are approved from age 12 in many countries.
- Women with PCOS: weight loss improves cycles and fertility; use reliable contraception during treatment.
- Elderly: focus on function and muscle; avoid large rapid weight loss.
- Kidney disease: GLP-1 drugs need no dose change, but watch for dehydration.
Remember for exams
- Drug therapy: BMI 30 or more, or 27 or more with a complication (lower in South Asians).
- Most effective: tirzepatide (about 20%), then semaglutide 2.4 mg (about 15%).
- Consider stopping if under 5% weight loss after 3 to 6 months at full dose.
- GLP-1 drugs: contraindicated with medullary thyroid cancer / MEN2 history and in pregnancy.
- Orlistat: lipase inhibitor; give fat-soluble vitamins.
- Tirzepatide reduces oral contraceptive effect.
Sources
- American Diabetes Association. Standards of Care in Diabetes 2026: Obesity and weight management.
- Trials: STEP 1 (semaglutide), SURMOUNT-1 (tirzepatide), SELECT (CV outcomes), OASIS 4 (oral semaglutide 25 mg), ATTAIN-1 (orforglipron).
- US FDA approvals: oral semaglutide 25 mg (December 2025), orforglipron (April 2026).
- Product information (SmPC/prescribing information) for individual drugs.
Important: this card is for education and revision. Treatment decisions must follow local guidelines and the treating doctor. More pocket cards: Clinical Pocket Cards
No comments:
Post a Comment